Immuno-chemotherapy in metastatic renal cell carcinoma: Long-term results from the Rambam and Linn Medical Centers, Haifa, Israel

Journal of Chemotherapy

Volumn 19, Issue 1, 2007, Pages 79-84

  Gez, Eliahu ^a,e   Rubinov, R ^b   Gaitini, D ^a   Meretyk, S ^a   Best, L A ^a   Mashiach, T ^a   Native, O ^c   Stein, A ^d   Kuten, A ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

^b Linn Medical Center   (Israel)

^c BNAI ZION MEDICAL CENTER   (Israel)

^d CARMEL MEDICAL CENTER   (Israel)

^e TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Immuno chemotherapy; Nephrectomy; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; FLUOROURACIL; INTERLEUKIN 2; VINBLASTINE;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FLU LIKE SYNDROME; HUMAN; ISRAEL; KIDNEY CARCINOMA; LIVER METASTASIS; LONG TERM CARE; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; TREATMENT RESPONSE;

EID: 33847002688     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2007.19.1.79     Document Type: Article

References (29)

1. th ed. Philadelphia: WB Saunders, 1993, Chapter 23.
2. Tigrani VS, Reese DM, Small EJ, Presti JC, Carroll PR. Potential role of nephrectomy in the treatment of metastatic renal cell carcinoma: A retrospective analysis. Urology 2000; 55:36-40
3. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R, and members of the European Organisation for Research and Treatment of Cancer Genitourinary Group. Radical nephrectomy plus interferon-alpha-based immunotherapy compared with interferon alpha alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358:966-70.
4. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al: Nephrectomy followed by interferon alfa-2b compared with Interferon alfa-2b alone for metastatic renal cell cancer. N Engl J Med 2001; 345:1655-9.
5. Sella A, Swanson DA, Ro JY, et al. Surgery following response to interferon-alpha-based therapy for residual renal cell carcinoma. J Urol 1993; 149:19-21.
6. Kim B, Louie AC. Surgical resection following interleukin 2 therapy for metastatic renal cekk carcinoma prolongs remission. Arch Surg 1992; 127:1343-9.
7. Cerfolio RJ, Allen MS, Deschamps C, et al. Pulmonary resection of metastatic renal cekk carcinoma. Ann Thorac Surg 1994; 57:339-44.
8. Kierney PC, Heerden JA, Segura JW, Weaver AL. Surgeon's role in the management of solitary renal cell carcinoma metastases occurring subsequent to initial curative nephrectomy: an institutional review. Ann Surg Oncol 1994; 1:345-52.
9. Atzpodien J, Korfe A, Franks CR, Poliwoda H, Kirchner H. Home therapy with recombinant interleukin-2 and interferon-a2b in advanced human malignancies. Lancet 1990; 335:1509-12.
10. Atzpodien J, Hanninen EL, Kirchner H, et al. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cekk carcinoma. J Clin Oncol 1995; 13:497-501.
11. Hanninen EL, Kirchner H, Atzpodien J. Interleukin-2 based home therapy of metastatic renal cekk carcinoma: Risks and benefits in 215 consecutive single institution patients. J Urol 1996; 155:19-25.
12. Gez E, Rubinov R, Gaitini D, Meretyk S et al: Interleukin-2, interferon-a, 5-fluorouracil and vinblastine in the treatment of metastatic renal cekk carcinoma. A prospective phase II study: The experience of Rambam and Linn Medical Centers 1996-2000. Cancer 2002; 95:1644-9.
13. Therasse P, Arbuck SG, Eisenhauer EA et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-16.
14. Irwin JO. Test of significance for differences between percentages based on small numbers. Metron 1935; 12:83-94.
15. Scheffe H. The Analysis of Variance. New York: John Wiley & Sons, 1995.
16. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50:163-70.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
18. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-19
19. Fyfe G, Fisher R I, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cekk carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995; 16:688-96.
20. Facendola G, Locatelli MC, Pizzocaro G, et al. Subcutaneous administration of interleukin-2 and inteferon-alpha-2b in advanced renal cell carcinoma: a confirmatory study. Br J Cancer 1995; 72: 1531-5.
21. Pectasides D, Varthalitis J, Kostopoulou M, et al. An outpatient phase II study of subcutaneous interleukin-2 and interferon-alpha-2b in combination with intravenous vinblastine in metastatic renal cell cancer. Oncology 1998; 55:10-5.
22. Revaud A, Audhuy B, Gomez F, et al. Subcutaneous interleukin-2, interferon alpha-2a and continuous infusion of fluorouracil in metastatic renal cekk carcinoma: a multicenter phase II trial. Group Francais de L'immunotherapie. J Clin Oncol 1998; 16:2728-32.
23. Samland D, Steinbach F, Reiher F, Schmidt U, Gruss A, Allhoff EP. Results of immuno-chemotherapy with interleukin-2, interferon-alpha2 and 5-fluorouracil in treatment of metastatic renal cell cancer. Eur Urol 1999; 35:204-9.
24. Rogers E, Bredin H, Butler M, Corcoran M, Egan E, Fennelly J, et al. Combined subcutaneous recombinant alpha-interferon and interleukin-2 in metastatic renal cell cancer: results of the multicenter All Ireland Immunotherapy Study Group. Eur Urol 2000; 37:37261-6.
25. Escudier B, Szczylik C, Eisen T et al: randomized Phase III trial of the Raf Kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma. ASCO 2005, Abstract #LB4510.
26. Stadler WM. Targeted agents for treatment of advanced renal cell carcinoma. Cancer 2005; 104:2323-33.
27. Hainsworth JD, Sosman JA, Spigel DR et al. Treatment of metastatic renal cekk carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005; 23:7889-96.
28. Rinit BI, Sosman JA and MotzertRJ. Therapy target at vascular endothelial growth factor in metastatic renal cekk carcinoma: biology, clinical results and future development. BJU International 2005: 96:286-90.
29. Leibovich BC, Han KR, Bui MHT, et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma. Cancer 2003; 98:2566-75.